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Background: Ipilimumab and vemurafenib have both been shown to improve survival in phase III trials of patients
with metastatic melanoma. Although vemurafenib is associated with a rapid onset of activity, responses are often of
limited duration. Conversely, responses to ipilimumab take time to develop, but can be durable. Currently, limited
data exist on the sequencing of these agents in patients with the BRAFV600 mutation. The aim of this analysis was
to identify factors that could potentially be used to optimise the order in which ipilimumab and BRAF inhibitors are
administered in this patient population.
Methods: This was a retrospective, single-institution, analysis of patients treated with vemurafenib 960 mg or
dabrafenib 150 mg twice-daily and ipilimumab 3 mg/kg every 3 weeks for 4 doses as part of a clinical trial or
expanded access program. Eligible patients tested positive for the BRAFV600 mutation and had sequentially received
treatment with vemurafenib or dabrafenib followed by ipilimumab, or vice versa.
Results: In total, 34 BRAF-mutation positive patients were eligible, comprising six patients who received ipilimumab
followed by a BRAF inhibitor, and 28 patients treated with a BRAF inhibitor who subsequently received ipilimumab.
Of these 28 patients, 12 (43%) had rapid disease progression resulting in death and were unable to complete
ipilimumab treatment as per protocol. These patients were classified as having rapid disease progression. Median
overall survival for rapid progressors was 5.7 months (95% CI: 5.0–6.3), compared with 18.6 months (95% CI: 3.2–
41.3; p< 0.0001) for those patients who were able to complete ipilimumab treatment. Baseline factors associated
with rapid progression were elevated lactate dehydrogenase, a performance status of 1 and the presence of brain
metastases. Patients were more likely to have rapid disease progression if they had at least two of these risk factors
at baseline.
Conclusions: Our analysis suggests it may be possible to identify those patients at high risk of rapid disease
progression upon relapse with a BRAF inhibitor who might not have time to subsequently complete ipilimumab
treatment. We hypothesise that these BRAF-mutation positive patients may benefit from being treated with
ipilimumab first.
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Until recently, patients with metastatic melanoma had
limited treatment options and a very poor prognosis. In
a meta-analysis of 42 phase II trials with 2,100 patients,
median survival was approximately 6 months, and only a
quarter of patients were alive after one year [1].
Despite many efforts over the past 30 years to improve
outcomes, no treatment was shown to improve survival
in metastatic melanoma [2]. However, due to significant
advances in our understanding of cancer immunology and
the molecular pathways involved in melanoma pathogen-
esis, the treatment landscape for metastatic melanoma
has, in recent times, undergone dramatic changes.
The recent approvals of vemurafenib and ipilimumab
means that physicians are now equipped with tools that
will allow some patients with metastatic melanoma to
live longer [3-5]. However, while both drugs have well-
documented benefits, they also have significant limita-
tions. Although treatment with BRAF inhibitors, such
as vemurafenib and dabrafenib, can result in the rapid
onset of tumour response in many patients, intrinsic
and/or acquired resistance means these are often tem-
porary, with a median time to progression of less than
7 months [5]. Furthermore, results from clinical trials of
vemurafenib suggest that progression can be rapid in
some patients. In the BRIM2 trial, among 39 patients
that died as a result of disease progression, 16 (41%)
died within 28 days of their last dose of vemurafenib [6].
In BRIM3, of 42 vemurafenib-treated patients who died
during the course of the study, 22 (52%) died within
28 days of their last dose, with almost all deaths attribu-
ted to disease progression [7]. By contrast, although ipi-
limumab has a slow onset of effect and a low rate of
objective responses, long-term follow-up from clinical
trials has demonstrated that responses can be durable
[8,9]. The two classes of agent therefore have very dif-
ferent, but potentially complimentary profiles, support-
ing a combination or sequencing approach to treatment.
Evidence suggests that BRAF inhibition and immunother-
apy may act synergistically. In preclinical studies, T-cell via-
bility and function was preserved when peripheral blood
mononuclear cells and BRAFV600E mutant melanoma cells
were exposed to clinically relevant concentrations of vemu-
rafenib in vitro [10]. In addition, an analogue of vemurafe-
nib was shown to increase both antigen presentation by
melanoma cells and their recognition by melanoma-specific
T cells [11]. Together, these studies support the rationale
that inhibition of BRAFV600 could render melanoma cells
more susceptible to attack by immunotherapeutic strat-
egies. However, further investigations are required to deter-
mine how the agents can be best used together to optimise
outcomes in those patients with a BRAFV600 mutation.
One strategy may be to use the two drugs sequentially;
for example, to start with a BRAF inhibitor to reducethe tumour load, then use ipilimumab to maintain the
response; or start with ipilimumab and provide vemura-
fenib afterwards to reduce the tumour burden.
Preclinical and clinical studies investigating the combi-
nation of immunotherapy and chemotherapy have high-
lighted that the sequence in which the agents are
administered can affect outcome [12,13]. The aims of this
retrospective study were to determine if the sequence in
which the BRAF inhibitors vemurafenib and dabrafenib
were administered with ipilimumab had an effect on clin-
ical outcome and to identify predictive factors that could
potentially be used to guide decisions regarding treatment.Methods
Patients
This was a single-institution, retrospective analysis of
patients treated within clinical trials or as part of an
expanded access program (EAP) at the National Cancer
Institute, Naples, Italy.
Patients were eligible for analysis if they tested posi-
tive for the BRAFV600 mutation and had sequentially
received vemurafenib or dabrafenib and ipilimumab, or
vice versa.
Patients could have received vemurafenib 960 mg twice
daily within the phase III BRIM3 study (NCT01006980) [3]
if they had previously untreated, unresectable, stage IIIC or
stage IV (metastatic) melanoma; or within the phase III
vemurafenib EAP (NCT01307397) [14] if they had previ-
ously untreated or pretreated metastatic melanoma.
Treatment naïve or previously treated patients with
metastatic melanoma could have received dabrafenib
150 mg twice daily within the phase II BREAK-2 trial
(NCT01153763) [15] or within the phase II BREAK-MB
trial (NCT01266967) if their melanoma had metastasised
to the brain [16].
Ipilimumab 3 mg/kg was administered intravenously
every 3 weeks for 4 doses as part of the ipilimumab EAP
(NCT00495066) for patients aged ≥ 16 years with unre-
sectable stage III/stage IV melanoma who had either
failed systemic therapy or were intolerant to ≥ 1 systemic
treatment and for whom no other therapeutic option
was available [17]. For patients treated with ipilimumab,
tumour assessments were performed according to im-
mune-related response criteria [18].
The protocols for the aforementioned studies were
approved by the institutional review board of the Na-
tional Cancer Institute, Naples, Italy and the studies
were all conducted in accordance with the ethical princi-
ples of the Declaration of Helsinki and within the Good
Clinical Practice guidelines, as defined by the Inter-
national Conference on Harmonization. All patients pro-
vided written informed consent before enrollment,
where applicable.
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Based on observations from the BRIM2 and BRIM3 clin-
ical trials that 40–50% of vemurafenib-treated patients
who died as a result of disease progression died within
28 days of the last vemurafenib dose [6,7], the primary aim
of this retrospective study was to identify baseline factors
that could be used to predict which BRAF inhibitor-treated
patients would experience rapid disease progression upon
relapse. Rapid progression was defined as not surviving
long enough to subsequently complete all four induction
doses of ipilimumab.
Patient and disease characteristics were summarised
using relative frequencies (percentages) for categorical
variables and median for continuous variables. Compari-
sons between the groups were performed using a two-
sided chi-square test. A logistic regression model was
used to determine if the following factors could be used
to predict which patients would complete ipilimumab
induction therapy: gender, age, Eastern Cooperative On-
cology Group performance status (ECOG PS), lactate
dehydrogenase (LDH) level, presence/absence of brain
metastases, previous lines of therapy and the BRAF
inhibitor used. Progression-free survival and overall sur-
vival were estimated using the Kaplan-Meier product-
limit method, with differences between curves evaluated
using the log-rank test.Results
Patients and treatment
In total, 34 BRAF-mutation positive patients were trea-
ted sequentially with a BRAF inhibitor and ipilimumab,
comprising six patients who received a BRAF inhibitor
upon disease progression with ipilimumab and 28 pa-
tients who received ipilimumab upon disease progres-
sion with a BRAF inhibitor. Among the 28 patients
treated with a BRAF inhibitor first, 12 (43%) received
vemurafenib and 16 (57%) received dabrafenib. Among
the six patients who received ipilimumab first, two (33%)
went on to receive dabrafenib and four (67%) received
vemurafenib. Baseline characteristics of the 34 patients
are summarised in Table 1. Characteristics were mostly
comparable between the two groups, although all patients
in the ipilimumab-first group had an ECOG PS of 0 com-
pared with 50% of patients in the BRAF inhibitor-first
group. Approximately two-thirds of patients included in
the analysis were male, half had elevated LDH and most
(31 out of 34; 91%) were metastatic stage M1c. All six
patients treated with ipilimumab first had received prior
treatment; therefore, ipilimumab represented the second
line of therapy in each case. Of patients treated with a
BRAF inhibitor, half had received prior therapy. Overall,
prior therapy comprised chemotherapy in 70% of patients
(n= 14) and immunotherapy with MAGE-A3 or targetedtherapy with a MEK inhibitor in 15% of patients, respect-
ively (n = 3 for each).
Treatment with ipilimumab followed by a BRAF inhibitor
All six patients were alive at the time of analyses with a
median follow-up of 11.2 months. Tumour responses
achieved with ipilimumab and subsequently with vemu-
rafenib or dabrafenib are provided in Table 2. Of the six
patients, three patients (50%) achieved immune-related
disease control (complete response [CR], partial re-
sponse [PR] or stable disease [SD]) with their initial ipili-
mumab treatment, and all six attained disease control
(a PR in five patients and SD in one) upon subsequent
treatment with a BRAF inhibitor.
The median time to disease progression with ipilimu-
mab treatment was 3.4 months (Table 2), which corre-
sponded exactly with the median time from progression
to initiating treatment with a BRAF inhibitor, suggesting
none of the patients had rapidly progressing disease.
Treatment with a BRAF inhibitor followed by ipilimumab
Tumour responses achieved with vemurafenib or dabra-
fenib and subsequently with ipilimumab are provided in
Table 2. Eighteen patients achieved disease control with
BRAF inhibition (64%), comprising one CR, 13 PRs and
five patients with SD. Upon subsequent treatment with
ipilimumab, the immune-related disease control rate was
50%, with seven patients each achieving a PR or SD.
Median time to disease progression was 3.6 months for
vemurafenib and 4 months for dabrafenib. However, the
median time from disease progression with a BRAF inhibi-
tor to starting treatment with ipilimumab was just 28 days.
Among the 28 patients, 12 had rapid disease progres-
sion resulting in death and were unable to complete all
four induction doses of ipilimumab 3 mg/kg as per proto-
col. For these patients, overall survival was 5.7 months
(95% CI: 5.0–6.3). The remaining 16 patients had slower
disease progression and were able to complete induction
therapy with ipilimumab. Median overall survival for these
patients was significantly longer at 18.6 months (95% CI:
3.2–41.3; p< 0.0001). Median overall survival for all 28
patients was 14.3 months (95% CI: 4.8–23.8).
The two groups of patients, subsequently classified as
rapid progressors or slow progressors, respectively, were
analysed according to baseline factors (Table 3). Univari-
ate analysis highlighted that being< 50 years of age, an
ECOG PS of 1, LDH level≥ 1.10 times the upper limit of
normal (ULN) and the presence of brain metastases
were all significantly associated with a poorer outcome;
i.e. with not completing the entire ipilimumab induction
regimen. In a multivariate analysis, LDH level and the
presence of brain metastases remained significant. Fur-
thermore, including ECOG PS in the model increased
the rate of correct classifications to 93%, suggesting that
Table 1 Baseline characteristics of patients treated









BRAF inhibitor, n (%)
Vemurafenib 12 (43) 4 (67)
Dabrafenib 16 (57) 2 (33)
Median age, years 50 48
Male/female,
n (%) / n (%)
18 (64) / 10 (36) 4 (67) / 2 (33)
ECOG PS
0 15 (54) 6 (100)
1 13 (46) 0 (0)
LDH level, n (%)
<1.10 ULN 14 (50) 3 (50)
≥1.10 ULN 14 (50) 3 (50)
Disease stage, n (%)
Unresectable IIIc 1 (4) 0 (0)
M1b 2 (7) 0 (0)
M1c 25 (89) 6 (100)
Brain metastasis, n (%) 7 (25) 3 (50)
Previous therapy, n (%) 14 (50) 6 (100)
Mage-A3 2 (7) 1(17)
Dacarbazine 5 (18) 1 (17)
Temozolomide
plus cisplatin
2 (7) 2 (33)
Cisplatin, vinblastine
and dacarbazine
3 (11) 0 (0)
Fotemustine 0 (0) 1 (17)
MEK inhibitor 2 (7) 1 (17)
ECOG PS, Eastern Cooperative Oncology Group performance status; LDH,
lactate dehydrogenase; ULN, upper limit of normal.
Table 3 Univariate analysis showing correlation between
baseline factors and completion of ipilimumab induction







Male 10 (56) 8 (44) 0.82
Female 6 (60) 4 (40)
Age
<50 years 5 (36) 9 (64) 0.02
≥50 years 11(79) 3 (21)
ECOG PS
0 12 (80) 3 (20) 0.009
1 4 (31) 9 (69)
Previous lines of therapy
0 9 (64) 5 (36) 0.44
1 7 (50) 7 (50)
Brain metastasis
Yes 0 (0) 7 (100) <0.0001
No 16 (76) 5 (24)
LDH
<1.10 ULN 13 (93) 1 (7) <0.001
≥1.10 ULN 3 (21) 11 (79)
BRAF inhibitor
Vemurafenib 7 (58) 5 (42) 0.91
Dabrafenib 9 (56) 7 (44)
ECOG PS, Eastern Cooperative Oncology Group performance status; LDH,
lactate dehydrogenase; ULN, upper limit of normal.
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rapid progression (Figure 1).
Additional analysis demonstrated a correlation between
the number of risk factors and completion of ipilimumabTable 2 Summary of tumour response and median time to pr
BRAF inhibitor followed by ipilimumab (n
Vemurafenib Dabrafenib Ip
Patients, n 12 16
Objective tumour
response*, n (%)
4 (33) 10 (63)
CR 0 (0) 1 (6)
PR 4 (33) 9 (56)
SD 4 (33) 1(6)
PD 4 (33) 5 (31)
Median time to progression,
months (95% CI)
3.6 (3.3–3.8) 4.0 (2.1–5.9)
*Determined at Week 12 among ipilimumab-treated patients according to immune
CI, confidence interval; CR, complete response; PD, progressive disease; PR, partial rinduction. Among patients treated with a BRAF inhibitor
prior to receiving ipilimumab, a maximum of one risk fac-
tor was associated with slow progression, while the pres-
ence of two or more risk factors was associated with rapid
progression (Table 4).
Discussion
For patients with BRAF-mutation positive metastatic
melanoma, vemurafenib and ipilimumab both representogression
=28) Ipilimumab followed by a BRAF inhibitor (n = 6)
ilimumab Ipilimumab Vemurafenib Dabrafenib
28 6 4 2
7 (25) 1 (17) 3 (75) 2 (100)
0 (0) 0 (0) 0 (0) 0 (0)
7 (25) 1 (17) 3 (75) 2 (100)
7 (25) 2 (33) 1 (25) 0 (0)
7 (25) 3 (50) 0 (0) 0 (0)
3.4 (2.8–4.1)
-related response criteria [18].
esponse; SD, stable disease.
Independent risk factors
ECOG PS = 1
LDH 1.10 x ULN
Presence of brain metastases
Maximum of one 
risk factor














Figure 1 Suggested algorithm for the sequential use of
ipilimumab and BRAF inhibitors in patients with metastatic,
BRAFV600 mutation-positive melanoma. Abbreviations: ECOG PS,
Eastern Cooperative Oncology Group Performance Status; LDH,
lactate dehydrogenase; ULN, upper limit of normal.
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of dabrafenib compared with dacarbazine has also re-
cently completed (NCT01227889) [19], with resultsTable 4 Correlation between number of baseline risk factors
every 3 weeks for a total of four doses)
0
Received BRAF inhibitor first and ipilimumab upon disease progression (n = 2
Slow progressors (n = 16) 11
Response to ipilimumab PR (n = 3); SD (n = 6); PD (n = 2)
Rapid progressors (n = 12) 0
Response to ipilimumab -
Received ipilimumab first and a BRAF inhibitor upon disease progression (n =
Completed induction regimen (n = 6) 2
Response to ipilimumab PR (n = 1); PD (n = 1)
NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.imminent. Following results from a phase I/II trial that
showed the combination of dabrafenib and trametinib, a
MEK inhibitor, had antitumour activity and a decreased
incidence of skin-related adverse events than dabrafenib
alone [20,21], randomised phase III trials comparing this
combination with dabrafenib alone (NCT01584648) or
vemurafenib alone (NCT01597908) are planned.
Treatment guidelines for metastatic melanoma stress
the importance of screening patients for mutations and
recommend that vemurafenib is preferentially used in
patients with BRAFV600 mutation-positive melanoma
who have symptomatic disease [22]. Vemurafenib is not
indicated for patients with wild-type BRAF [23]. By con-
trast, ipilimumab can be used to treat patients with
metastatic melanoma, regardless of their BRAF status. In
a retrospective analysis of tumour biopsies from patients
treated with ipilimumab in a phase II clinical trial, rates
of objective responses and stable disease in patients with
BRAFV600E mutation-positive tumours were comparable
with those in patients with the wild-type gene [24].
Historically, oncologists were used to responses to
conventional anticancer therapies like chemotherapy oc-
curring within days or weeks of starting treatment. Im-
portantly, ipilimumab is associated with unique patterns
of response, related to its mechanism of action, which
can influence treatment choice. Because it can take
weeks to months to build a complete immune response
against a tumour, responses with ipilimumab may not be
detectable until Week 12 of treatment. Furthermore,
during this period the cancer may progress or appear to
progress [18,25]. Because the timing of responses is dif-
ferent, ipilimumab treatment may not be appropriate for
those patients who have rapidly progressing disease. If a
physician considers that their patient will not have time
to complete the 12-week induction course and wait for a
response, then other treatment options should be con-
sidered [26]. Although clinical success is noted for
vemurafenib, treatment with this agent as the first stage
of a sequential strategy may also present difficulties.and completion of ipilimumab induction therapy (3 mg/kg




PR (n = 3) PR (n = 1); PD (n = 1) -
1 7 4
SD (n= 1) NE (n = 4); PD (n = 3) NE (n = 3); PD (n = 1)
6)
2 2 0
PD (n= 2) SD (n = 2) -
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they may subsequently relapse and progress. If disease
progression is rapid, the patient may not have the time
available to them to respond to subsequent immuno-
therapy [26].
Previous studies have highlighted an older age, poor
performance status and male gender to be associated
with poor prognosis in patients with melanoma [27].
More recently, elevated LDH levels have also emerged as
a significant negative prognostic indicator [28,29]. His-
torically, those patients with advanced disease and brain
metastases have also had a particularly poor prognosis,
with a life expectancy of only 3–5 months [30,31].
Nevertheless, there is now some renewed hope for
these patients. Subgroup analyses of clinical trials have
suggested that the effect of ipilimumab and vemurafenib
on overall survival is independent of age, gender, base-
line LDH and metastatic stage of disease [3,4,26]. Fur-
thermore, preliminary studies suggest ipilimumab and
BRAF inhibitors may also have activity in patients with
melanoma brain metastases [32-34]. These findings indi-
cate that patients with baseline characteristics associated
with high-risk, symptomatic disease can potentially
benefit from treatment with both BRAF inhibitors and
ipilimumab [4,26]. The question our study aimed to ad-
dress was, based on baseline factors; can we determine
which patients are more likely to have rapid disease pro-
gression after developing resistance to BRAF inhibitors
and would therefore be less likely to be able to receive
subsequent treatment with ipilimumab? That is, can we
determine the optimal sequence in which these agents
should be used?
In this retrospective analysis, among 28 patients trea-
ted with a BRAF inhibitor first, almost half were unable
to complete treatment with ipilimumab due to rapid dis-
ease progression. The most significant risk factors for
rapid progression were elevated LDH, a PS of 1 and the
presence of brain metastases. Although this was a retro-
spective study of a small number of patients, the data
suggest that the presence of two or more of these risk
factors may predict for rapid disease progression. Our
hypothesis is that patients with two or more risk factors
could potentially benefit from receiving ipilimumab as the
first part of their sequential treatment regimen (Figure 1).
It is important to note, however, that among the six
patients who received ipilimumab first and were subse-
quently treated with a BRAF inhibitor upon disease pro-
gression, there was no correlation between the number of
risk factors at baseline and rate of progression (Table 4).
Interestingly, in a post-hoc analysis of patients from
BRIM3 treated with vemurafenib, there was a 50% re-
duction in the risk of death for patients with LDH
greater than the ULN, and a 48% reduction in the risk of
death for patients with an ECOG PS of 1. Bycomparison, the risk of death was reduced by 35%
among patients with normal LDH and 36% for patients
with an ECOG PS of 0 [23]. These results suggest that
the benefit of vemurafenib is greater in patients with
negative prognostic factors, which is perhaps unsurpris-
ing as patients with the poorest prognosis would poten-
tially have the most to gain from treatment.
It is possible that patients who are at risk of rapid disease
progression according to our proposed algorithm would
benefit from concomitant treatment with ipilimumab and
a BRAF inhibitor. The safety and efficacy of ipilimumab
and vemurafenib combination therapy is currently being
assessed in a prospective, multicenter phase I/II trial
(NCT01400451) of patients with BRAF V600 mutation-
positive metastatic melanoma to determine whether add-
itional benefits are possible with combination therapy
compared with the use of either agent alone or their se-
quential use; however, results from this study are not due
until 2015. In the meantime, two agents are currently avail-
able for clinical use that, from this analysis, would appear
to work better when used in sequence rather than as indi-
vidual monotherapies. All patients in this analysis received
the second of their sequential treatments after disease
progression had been documented. It is possible that
switching prior to disease progression in BRAF mutation-
positive patients, i.e. when the patient has achieved disease
control, would result in more durable outcomes. The opti-
mal timing of sequential therapy, however, requires further
clinical investigation.Conclusions
The results of this preliminary analysis suggest that it
may be possible to determine the optimal sequence of
treatments in patients with BRAF mutation-positive
metastatic melanoma based on presence of specific risk
factors; however, further investigation in a larger number
of patients is required to validate this hypothesis.
The optimal sequencing paradigm for patients with
metastatic melanoma has not yet been fully determined.
However, the availability of two new agents that provide
an overall survival benefit in phase III clinical trials has
brought hope to a therapy area that previously relied on
enrolment into a clinical trial as the best option. Optimi-
sation of treatment strategies in the future will provide
additional clinical benefit for patients with metastatic
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